Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: Cage Rattler who wrote (652)	10/29/1998 10:06:00 AM
From: Michael Olin	Read Replies (1) \| Respond to of 1255

At $3 Cortex was a crap shoot. Any biotech of this size (very small) without a proven pipeline and no partners for trials, NDA, marketing and distribution is a crap shoot. The only thing to base an investment on is the science. If the compounds that Cortex has in trials prove to be safe and effective, and they get FDA approval, and they partner with someone to market the drug(s), Cortex will have been, in 20/20 hindsight, a good investment at $3 or $6 or $.75. There is nothing new that is publicly known about the company, other than the CFO's departure, with no reason given, to justify price moves in any direction. It is all speculation (or perhaps gambling is a more appropriate description). Why would you expect Cortex to "display positive growth" if we still don't know if they even have a marketable product? The value of Cortex is not whatever its stock price is today. The chances of the stock going down (or up) on no news depends solely on which way the traders decide to go. The value of Cortex is in its as yet unproven intellectual property. -Michael